Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)Volunteer Subjects
- Interventions
- Biological: Lipidomic analysesOther: Adapted physical activity program
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 54
- Registration Number
- NCT06944548
- Locations
- 🇫🇷
CHU Dijon (clinical investigation centre), Dijon, France
🇫🇷Centre Georges-François Leclerc, Dijon, France
Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.
Not Applicable
Recruiting
- Conditions
- All Types of Metastatic Solid Malignancy1st-line TreatmentExome AnalysisActive File EXOMA2 Study
- Interventions
- Other: Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 80
- Registration Number
- NCT06550687
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷CHU François Mitterand, Dijon, France
🇫🇷Centre Georges-François Leclerc, Dijon, France
Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.
Not Applicable
Not yet recruiting
- Conditions
- Patients With Metastatic Castration-resistant Prostate Cancer
- Interventions
- Radiation: 177Lu-PSMA-617 PET scan
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 35
- Registration Number
- NCT06136377
Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: QuestionnairesOther: Communication of the results of the BRCA1/2 ultra rapid test
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 150
- Registration Number
- NCT06111417
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷Institut Rafaël, Levallois-perret, France
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy
Phase 2
Recruiting
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Drug: FOLFIRINOX treatment
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 90
- Registration Number
- NCT05988814
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 24
- Registration Number
- NCT05937906
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Burgundy, France
Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
Not Applicable
Recruiting
- Conditions
- Patient With Radiotherapy (Linac MRI)Mobile Cancerous Lesion
- Interventions
- Combination Product: With non-magnetic screen
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 100
- Registration Number
- NCT05783908
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Côte d'Or, France
Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: PlaceboDrug: OnLife®
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 60
- Registration Number
- NCT05695313
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV
Not Applicable
Recruiting
- Conditions
- Non-small Cell Bronchopulmonary Carcinoma at Stage IV and Benefiting From First-line Treatment According to Current French Recommendations
- Interventions
- Other: Test Leeds Food Preference Questionnaire (LFQP-France)
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 190
- Registration Number
- NCT05496556
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Côte d'Or, France
Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration
Not Applicable
Recruiting
- Conditions
- Localized Breast Cancer
- Interventions
- Drug: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)Drug: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 100
- Registration Number
- NCT05296317
- Locations
- 🇫🇷
Centre Georges François Leclerc (CGFL), Dijon, Bourgogne, France
© Copyright 2025. All Rights Reserved by MedPath